Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

101. The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac bypass surgery in adults: a systematic review protocol. Full Text available with Trip Pro

The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac bypass surgery in adults: a systematic review protocol. 26447069 2016 04 22 2018 12 02 2202-4433 13 4 2015 May 15 JBI database of systematic reviews and implementation reports JBI Database System Rev Implement Rep The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac bypass surgery in adults (...) : a systematic review protocol. 3-13 10.11124/jbisrir-2015-1675 Pearce Anna A Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, South Australia. Lockwood Craig C Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, South Australia. Van Den Heuvel Corinna C School of Medical Sciences, The University of Adelaide, South Australia. eng Journal Article 2015 05 15 Australia JBI Database System Rev Implement Rep 101648258 2202-4433 I38ZP9992A Magnesium IM

2015 JBI database of systematic reviews and implementation reports

102. Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines

Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical (...) Effectiveness and Guidelines Published on: September 2, 2015 Project Number: RB0906-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous administration of magnesium sulphate for the treatment of acute and unrelieved, refractory asthma-related bronchospasm in prehospital settings? What are the evidence-based guidelines regarding the intravenous administration of magnesium sulphate for the treatment of acute

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

103. Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency

Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency Final Appraisal Recommendation Advice No: 2215 – July 2015 Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution Limited submission by Kora Healthcare Additional note(s): • Magnaspartate ® is the first licensed oral magnesium product available in Wales for the treatment and prevention of magnesium deficiency. In reaching the above recommendation AWMSG has taken (...) every three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2215: Magnesium aspartate dihydrate (Magnaspartate ® ) 243 mg powder for oral solution. July 2015. Recommendation of AWMSG Magnesium aspartate dihydrate (Magnaspartate ® ) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency

2015 All Wales Medicines Strategy Group

104. Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block?

Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? BestBets: Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Report By: Dr Peter Kilgour, Dr Babajide Oni - Emergency Medicine ST2 Search checked by Dr Dianne Tabone , Dr Hisham Ghanayem (ST5) - Consultant in Emergency Medicine Preston and (ST5 Central Manchester (...) ) Institution: Royal Preston Hospital, Preston, Lancs, UK Date Submitted: 11th November 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with a femoral neck fracture] does [magnesium prolong the analgaesic effect of bupivacaine] in [a fascia iliaca nerve block]? Clinical Scenario An 89-year-old woman presents to your emergency department following a fall. She is complaining of severe pain in her right hip area. A plain radiograph shows

2015 BestBETS

105. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. Full Text available with Trip Pro

Prehospital use of magnesium sulfate as neuroprotection in acute stroke. Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents.We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning (...) within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age

2015 NEJM Controlled trial quality: predicted high

106. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations?

Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? Systematic Review Snapshot TAKE-HOME MESSAGE Administration of intravenous magnesium sulfate may result in a modest reduction in hospital admissions among adult ED patients with acute asthma who have not responded to standard therapies. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? EBEM Commentators (...) intravenous magnesium sulfate during 15 to 30 minutes experienced a small but signi?cant reduction in rates of hospital admission (odds ratio [OR] 0.75), with minimal heterogeneity observed (I 2 ¼28%). When the 3 studies at high or unclear risk of bias for blinding were removed, the pooled effect for hospital admission was similar (OR 0.72; 95% con?dence interval [CI] 0.57 to 0.91). There was no signi?cant change in spirometric parameters (eg, peak expiratory ?ow) as well. All studies included

2015 Annals of Emergency Medicine Systematic Review Snapshots

107. Prevalence and clinical impact of magnesium disorders in end stage renal disease: a protocol for a systematic review

Prevalence and clinical impact of magnesium disorders in end stage renal disease: a protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

108. The prognostic effect of serum magnesium in patients with heart failure

The prognostic effect of serum magnesium in patients with heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2015 PROSPERO

109. The effectiveness of essential fatty acid, B vitamin, Vitamin C, magnesium and zinc supplementation for managing stress in women: a systematic review protocol

The effectiveness of essential fatty acid, B vitamin, Vitamin C, magnesium and zinc supplementation for managing stress in women: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2015 PROSPERO

110. Magnesium to prevent arrhythmias in patients undergoing cardiothoracic surgery: a systematic review and meta-analysis

Magnesium to prevent arrhythmias in patients undergoing cardiothoracic surgery: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

111. Magnesium for treating sickle cell disease [Cochrane Protocol]

Magnesium for treating sickle cell disease [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

112. Low magnesium levels in metabolic syndrome: evidence from meta-analysis

Low magnesium levels in metabolic syndrome: evidence from meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2015 PROSPERO

113. Effect of nebulised magnesium sulphate on length of hospital stay as compared to other treatment in bronchiolitis: a systematic review and meta-analysis

Effect of nebulised magnesium sulphate on length of hospital stay as compared to other treatment in bronchiolitis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

114. Different treatment regimens for magnesium sulphate for tocolysis in women in preterm labour for improving health outcomes [Cochrane Protocol]

Different treatment regimens for magnesium sulphate for tocolysis in women in preterm labour for improving health outcomes [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

115. The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac bypass surgery in adults: a systematic review protocol

The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac bypass surgery in adults: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2015 PROSPERO

116. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department [Cochrane Protocol]

Intravenous magnesium sulfate for treating children with acute asthma in the emergency department [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

117. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department [Cochrane Protocol]

Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

118. Sodium picosulfate plus magnesium citrate regimens versus polyethylene glycol-based regimens for bowel cleansing before colonoscopy

Sodium picosulfate plus magnesium citrate regimens versus polyethylene glycol-based regimens for bowel cleansing before colonoscopy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

119. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation Full Text available with Trip Pro

Intrapartum magnesium sulfate and need for intensive delivery room resuscitation To evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection (MgSO4-FN) with the delivery room resuscitation and neonatal outcomes of preterm infants in an era of minimisation of invasive mechanical ventilation.Retrospective cohort study.Neonatal intensive care units in the Canadian Neonatal Network.Preterm infants (23(0) to 31(6) weeks gestational age) born in 2011 or 2012. Resuscitation

2014 EvidenceUpdates

120. Magnesium sulphate for preventing preterm birth in threatened preterm labour. (Abstract)

Magnesium sulphate for preventing preterm birth in threatened preterm labour. Magnesium sulphate has been used in some settings as a tocolytic agent to inhibit uterine activity in women in preterm labour with the aim of preventing preterm birth.To assess the effects of magnesium sulphate therapy given to women in threatened preterm labour with the aim of preventing preterm birth and its sequelae.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (last searched 31 January (...) 2014).Randomised controlled trials of magnesium sulphate as the only tocolytic, administered by any route, compared with either placebo, no treatment or alternative tocolytic therapy (not magnesium sulphate) to women considered to be in preterm labour.At least two review authors assessed trial eligibility and risk of bias and undertook data extraction independently.The 37 included trials (total of 3571 women and over 3600 babies) were generally of moderate to high risk of bias. Antenatal magnesium

2014 Cochrane